NADER NAJAFIAN, MD
Osteopathic Medicine at Francis St, Boston, MA

License number
Massachusetts 154194
Category
Osteopathic Medicine
Type
Nephrology
Address
Address 2
75 Francis St, Boston, MA 02115
111 Cypress St, Brookline, MA 02445
Phone
(617) 732-5868
(857) 307-0896

Organization information

See more information about NADER NAJAFIAN at bizstanding.com

Nader Najafian MD

75 Francis St, Boston, MA 02115

Industry:
Internist
Phone:
(617) 732-5868 (Phone)
Nader Najafian

Professional information

Nader Najafian Photo 1

Nader Najafian, Weston FL

Specialties:
Nephrologist
Address:
2950 Cleveland Clinic Blvd, Weston, FL 33331
111 Cypress St, Brookline, MA 02445
75 Francis St, Boston, MA 02115
Education:
University of Vienna, Faculty of Medicine - Doctor of Medicine*
Board certifications:
American Board of Internal Medicine Certification in Internal Medicine*, American Board of Internal Medicine Sub-certificate in Nephrology (Internal Medicine)*


Nader Najafian Photo 2

Nader Najafian, Boston MA

Specialties:
Internal Medicine, Nephrology, Pulmonary Disease
Work:
Brigham & Women's Hospital
75 Francis St, Boston, MA 02115 Transplantation Research Center
221 Longwood Ave, Boston, MA 02115
Education:
Universitat Wien (1995)


Nader Najafian Photo 3

Nader Najafian

Location:
Greater Boston Area
Industry:
Hospital & Health Care


Nader Najafian Photo 4

Methods Of Using Anti-Thymocyte Globulin And Related Agents

US Patent:
2010003, Feb 11, 2010
Filed:
May 31, 2007
Appl. No.:
12/302598
Inventors:
Nader Najafian - Brookline MA, US
Mohamed H. Sayegh - Westwood MA, US
Melanie Ruzek - Danielson CT, US
Srinivas Shankara - Shrewsbury MA, US
John Williams - Hopkinton MA, US
Johanne Kaplan - Sherborn MA, US
John M. McPherson - Hopkinton MA, US
International Classification:
A61K 35/18, A61K 38/17, A61P 37/00, C12N 5/0783
US Classification:
424 937, 514 12, 4353723
Abstract:
Uses for anti-thymocyte globulin (ATG, e.g., Thymoglobulin®) and related compositions are described. In one aspect, ATG and, optionally, TGF-beta are used for in vitro generation of regulatory T cells, which are useful for cell therapy of immune-mediated conditions. In another aspect, ATG is directly administered to a subject at a low dose (e.g., less than 1 mg/kg per day) to treat an immune-mediated condition. The immune-mediated conditions include, for example, transplant rejection, graft-versus-host disease, and autoimmune diseases.